Skip to content

A prospective cohort study on the etiology screening of endocrine hypertension

A prospective cohort study on the etiology screening of endocrine hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075747
Enrollment
Unknown
Registered
2023-09-14
Start date
2023-04-28
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocrine hypertension

Interventions

Normal high value group/New onset hypertension group/Refractory hypertension group/Good blood pressure control group:N/A

Sponsors

Beijing Children's Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 or older, informed consent, and meets one of the following conditions: 1.Patients who are newly diagnosed with hypertension (according to the Chinese Guidelines for the Prevention and Treatment of Hypertension, 2018 revised edition) and have not used antihypertensive drugs, with clinic systolic blood pressure (SBP) = 140 mmHg and/or diastolic blood pressure (DBP) = 90 mmHg; 2.Patients with well-controlled blood pressure who voluntarily agree to participate; 3.Patients with refractory hypertension who have taken three antihypertensive drugs at a tolerable and reasonable dose, including a thiazide diuretic, for at least 4 weeks and still have blood pressure values above the target level in the clinic and outside the clinic (including home blood pressure or ambulatory blood pressure monitoring), or patients who need at least 4 drugs to achieve blood pressure control; 4.Patients with high-normal blood pressure, with clinic SBP 120-139 mmHg and/or DBP 80-89 mmHg, and have one of the following high-risk factors: overweight, obesity, alcohol consumption, abnormal blood glucose, and abnormal triglycerides.

Exclusion criteria

Exclusion criteria: 1.Patients with severe liver dysfunction, congenital heart disease, malignant tumors, and severe infections; 2.Patients with severe mental illness or cognitive impairment; 3.Patients who are difficult to follow-up or cannot provide informed consent.

Design outcomes

Primary

MeasureTime frame
Prevalence of endocrine hypertension;

Secondary

MeasureTime frame
Aldosterone;Angiotensin I;Plasma renin activity;Dopamine;Adrenaline;Noradrenaline;Hydrocortisone;11- deoxycortisol;21- deoxycortisol;Corticosterone;Blood potassium;Blood routine;Liver function;Renal function;Imaging indicators;Inflammatory cytokine;

Countries

China

Contacts

Public ContactAihua Hu

Beijing Children's Hospital, Capital Medical University

aihuacn@hotmail.com+86 188 1173 1250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026